Treatment of patients with lipid disorders in the primary care setting: New treatment guidelines and their implications

Southern Medical Journal

Volumn 96, Issue 3, 2003, Pages 266-275

  Keenan, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; HEALTH CARE COST; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIMARY MEDICAL CARE; REVIEW;

ANTICHOLESTEREMIC AGENTS; CORONARY DISEASE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; LIFE STYLE; PRACTICE GUIDELINES; RISK ASSESSMENT;

EID: 0037343978     PISSN: 00384348     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.SMJ.0000061513.59902.6A     Document Type: Review

References (101)

1. American Heart Association. 2002 Heart and Stroke - Statistical Update. Dallas, American Heart Association, 2001.
2. Kannel WB, Castelli WP, Gordon T, McNamara PM. Serum cholesterol, lipoproteins, and the risk of coronary heart disease: The Framingham study. Ann Intern Med 1971;74:1-12.
3. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
4. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: The Framingham Study. JAMA 1986;256:2835-2838.
5. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: A meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213-219.
6. Miller M, Seidler A, Moalemi A, Pearson TA. Normal triglyceride levels and coronary artery disease events: The Baltimore Coronary Observational Long-Term Study. J Am Coll Cardiol 1998;31:1252-1257.
7. Castelli WP. Epidemiology of triglycerides: A view from Framingham. Am J Cardiol 1992;70:3H-9H.
8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-2497.
9. Crouch MA. Effective use of statins to prevent coronary heart disease. Am Fam Physician 2001;63:309-324.
10. Okada M, Ishida R. Direct measurement of low-density-lipoprotein cholesterol is more effective than total cholesterol for the purpose of lipoprotein screening. Prev Med 2001;32:224-229.
11. Watts GF, Lewis B, Brunt JN, Lewis ES, Coltart DJ, Smith LD, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
12. Arntzenius AC, Kromhout D, Barth JD, Reiber JH, Bruschke AV, Buis B, et al. Diet, lipoproteins, and the progression of coronary atherosclerosis: The Leiden Intervention Trial. N Engl J Med 1985; 312:805-811.
13. Ornish D, Brown SE, Scherwitz LW, Billings JH, Armstrong WT, Ports TA, et al. Can lifestyle changes reverse coronary heart disease? The Lifestyle Heart Trial. Lancet 1990;336:129-133.
14. Blankenhorn DH, Johnson RL, Mack WJ, el Zein HA, Vailas LI. The influence of diet on the appearance of new lesions in human coronary arteries. JAMA 1990;263:1646-1652.
15. Gaddi A, Descovich GC, Noseda G, Fragiacomo C, Colombo L, Craveri A, et al. Controlled evaluation of pantethine, a natural hypolipidemic compound, in patients with different forms of hyperlipoproteinemia. Atherosclerosis 1984;50:73-83.
16. Bertolini S, Donati C, Elicio N, Daga A, Cuzzolaro S, Marcenaro A, et al. Lipoprotein changes induced by pantethine in hyperlipoproteinemic patients: Adults and children. Int J Clin Pharmacol Ther Toxicol 1986;24:630-637.
17. Heinemann T, Kullak-Ublick GA, Pietruck B, von Bergmann K. Mechanisms of action of plant sterols on inhibition of cholesterol absorption: Comparison of sitosterol and sitostanol. Eur J Clin Pharmacol 1991;40(Suppl 1):S59-S63.
18. Neil HA, Meijer GW, Roe LS. Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis 2001;156:329-337.
19. Law M. Plant sterol and stanol margarines and health. BMJ 2000;320: 861-864.
20. Welty FK, Stuart E, O'Meara M, Huddleston J. Effect of addition of exercise to therapeutic lifestyle changes diet in enabling women and men with coronary heart disease to reach Adult Treatment Panel III low-density lipoprotein cholesterol goal without lowering high-density lipoprotein cholesterol. Am J Cardiol 2002;89:1201-1204.
21. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia - Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245.
22. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418.
23. Israeli Society for Prevention of Heart Attacks. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000;102:21-27.
24. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
25. Knopp RH, Ginsberg J, Albers JJ, Hoff C, Ogilvie JT, Warnick GR, et al. Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: Clues to mechanism of action of niacin. Metabolism 1985;34:642-650.
26. McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-677.
27. a. Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang Z, Ripsin CM. A randomized, controlled trial of wax-matrix sustained-released niacin hypercholesterolemia. Arch Intern Med 1991;151:1424-1432.
28. Gurakar A, Hoeg JM, Kostner G, Papadopoulos NM, Brewer HB Jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985;57:293-301.
29. Dalessandri KM. Multiple methods for reduction of lipoprotein(a). Atherosclerosis 2002;163:409-410 (letter).
30. Capuzzi DM, Guyton JR, Morgan JM, Goldberg AC, Kreisberg RA, Brusco OA, et al. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study. Am J Cardiol 1998;82:74U-86U.
31. Goldberg A, Alagona P Jr, Capuzzi DM, Guyton J, Morgan JM, Rodgers J, et al. Multiple-dose efficacy and safety of an extendedrelease form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-1105.
32. Hiatt JG, Shamsie SG, Schectman G. Discontinuation rates of cholesterol-lowering medications: Implications for primary care. Am J Manag Care 1999;5:437-444.
33. Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (CholestaGel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med 1999;159:1893-1900.
34. Insull W Jr, Toth P, Mullican W, Hunninghake D, Burke S, Donovan JM, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: A 24-week randomized controlled trial. Mayo Clin Proc 2001;76:971-982.
35. Aldridge MA, Ito MK. Colesevelam hydrochloride: A novel bile acidbinding resin. Ann Pharmacother 2001;35:898-907.
36. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207-213.
37. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. Arterioscler Thromb Vasc Biol 1999;19:187-195.
38. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-1307.
39. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS - Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-1622.
40. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344: 1383-1389.
41. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events Trial Investigators. N Engl J Med 1996;335:1001-1009.
42. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339:1349-1357.
43. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360: 7-22.
44. Clearfield M, Whitney EJ, Weis S, Downs JR, Shapiro DR, Stein EA, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Baseline characteristics and comparison with USA population. J Cardiovasc Risk 2000;7:125-133.
45. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-620.
46. The Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenousvein coronary-artery bypass grafts. N Engl J Med 1997;336:153-162.
47. Pitt B, Waters D, Brown WV, van Boven AJ, Schwartz L, Title LM, et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease: Atorvastatin versus Revascularization Treatment Investigators. N Engl J Med 1999;341:70-76.
48. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999;99:736-743.
49. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279:1643-1650.
50. Laufs U, Liao JK. Direct vascular effects of HMG-CoA reductase inhibitors. Trends Cardiovasc Med 2000;10:143-148.
51. Vaughan CJ, Gotto AM Jr, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000;35:1-10.
52. LaRosa JC. Pleiotropic effects of statins and their clinical significance. Am J Cardiol 2001;88:291-293.
53. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein: The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.
54. Deleted in proof.
55. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998;97:2007-2011.
56. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99:237-242.
57. Rohde LE, Hennekens CH, Ridker PM. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 1999;84:1018-1022.
58. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836-843.
59. Niwa S, Totsuka T, Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol 1996;18:669-675.
60. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf 2000;23:197-213.
61. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001;2:205-207.
62. De Pinieux G, Chariot P, Ammi-Said M, Louarn F, Lejonc JL, Astier A, et al. Lipid-lowering drugs and mitochondrial function: Effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 1996;42:333-337.
63. Wilkins DJ, Bliznakov EG. Biochemical and clinical consequences of inhibiting coenzyme Q10 biosynthesis by lipid-lowering HMG-CoA reductase inhibitors (statins): A critical overview. Adv Ther 1998; 15: 218-228.
64. Ogasahara S, Engel AG, Frens D, Mack D. Muscle coenzyme Q deficiency in familial mitochondrial encephalomyopathy. Proc Natl Acad Sci U S A 1989;86:2379-2382.
65. Muck W, Ritter W, Ochmann K, Unger S, Ahr G, Wingender W, et al. Absolute and relative bioavailability of the HMG-CoA reductase inhibitor cerivastatin. Int J Clin Pharmacol Ther 1997;35:255-260.
66. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001;87:28B-32B.
67. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999;84:413-428.
68. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996;275:55-60.
69. Lewis SJ, Sacks FM, Mitchell JS, East C, Glasser S, Kell S, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: The cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol 1998;32:140-146.
70. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-519.
71. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001;110:716-723.
72. Pfeffer MA, Keech A, Sacks FM, Cobbe SM, Tonkin A, Byington RP, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002;105: 2341-2346.
73. Orsi A, Sherman O, Woldeselassie Z. Simvastatin-associated memory loss. Pharmacotherapy 2001;21:767-769.
74. Partonen T, Haukka J, Virtamo J, Taylor PR, Lonnqvist J. Association of low serum total cholesterol with major depression and suicide. Br J Psychiatry 1999;175:259-262.
75. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-1631.
76. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57: 1439-1443.
77. Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database Syst Rev 2001;4:CD003160.
78. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:M414-M418.
79. Muldoon MF, Manuck SB, Mendelsohn AB, Kaplan JR, Belle SH. Cholesterol reduction and non-illness mortality: Meta-analysis of randomised clinical trials. BMJ 2001;322:11-15.
80. Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER): PROSPER Study Group - PROspective Study of Pravastatin in the Elderly at Risk. Am J Cardiol 1999;84:1192-1197.
81. Ford I, Blauw G, Murphy MB, Shepherd J, Cobbe SM, Bollen EL, et al. The PROSPER Study Group. A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics. Curr Control Trials Cardiovasc Med 2002;3:8.
82. Beaird SL. HMG-CoA reductase inhibitors: Assessing differences in drug interactions and safety profiles. J Am Pharm Assoc (Wash) 2000; 40:637-644.
83. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: The role of metabolismmonograph for physicians. Arch Intern Med 2000;160:2273-2280.
84. Deleted in proof.
85. Huse DM, Russell MW, Miller JD, Kraemer DF, D'Agostino RB, Ellison RC, et al. Cost-effectiveness of statins. Am J Cardiol 1998; 82:1357-1363.
86. Pickin DM, McCabe CJ, Ramsay LE, Payne N, Haq IU, Yeo WW, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-332.
87. Shepherd J. Economics of lipid lowering in primary prevention: Lessons from the West of Scotland Coronary Prevention Study. Am J Cardiol 2001;87:19B-22B.
88. Tsevat J, Kuntz KM, Orav EJ, Weinstein MC, Sacks FM, Goldman L. Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels. Am Heart J 2001;141:727-734.
89. Mark DB, Hlatky MA, Califf RM, Naylor CD, Lee KL, Armstrong PW, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
90. Kuntz KM, Tsevat J, Goldman L, Weinstein MC. Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation 1996;94:957-965.
91. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160:459-467.
92. Abookire SA, Karson AS, Fiskio J, Bates DW. Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Arch Intern Med 2001;161:53-58.
93. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: Efficacy and safety. J Intern Med 2000;247:563-569.
94. Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998;82:57U-66U, 86U.
95. Luc G, Bard JM, Arveiler D, Ferrieres J, Evans A, Amouyel P, et al. Lipoprotein (a) as a predictor of coronary heart disease: The PRIME Study. Atherosclerosis 2002;163:377-384.
96. Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990;264:71-75.
97. Van Heek M, France CF, Compton DS, McLeod RL, Yumibe NP, Alton KB, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther 1997;283:157-163.
98. Kosoglou T, Seiberling M, Statkevich P, Cutler DL, Yang B, Anderson L, et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001;37(2 Suppl A):229A (abstr).
99. Insull W Jr, Koren M, Davignon J, Sprecher D, Schrott H, Keilson LM, et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001;157:137-144.
100. Davidson M, Ma P, Stein EA, Gotto AM Jr, Raza A, Chitra R, et al. Comparison of effects on low-density lipoprotein cholesterol and highdensity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa of IIb hypercholesterolemia. Am J Cardiol 2002; 89:268-275.
101. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: A randomized, double-blind study. J Cardiovasc Risk 2001; 8:383-390.